Alnylam Pharmaceuticals has capped off a busy month of breakthrough therapy recipients, with the company announcing the designation May 31 for its ALN-AS1 (givosiran) an RNAi treatment designed for the prevention of attacks in patients with acute hepatic porphyria.
A family of rare diseases, acute hepatic porphyrias can result in patients experiencing severe neurovisceral attacks that can lead to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?